Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide plus oral etoposide in relapsed or refractory pediatric embryonal and malignant glial brain tumors
2006-000570-78Phase 2Completed
- Sponsor
- Policlinico Gemelli
- Start
- Nov 2006
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of temozolomide and etoposide in supratentorial embryonal tumor, medulloblastoma and malignant glioma (2 cohorts), sponsored by Policlinico Gemelli. Primary endpoints: Toxicity and Maximum tolerated dose. Started Nov 2006; status: completed.
02
Drugs
temozolomideetoposide
03
Conditions
supratentorial embryonal tumormedulloblastomamalignant glioma
Beyond the preview
Go deeper on 2006-000570-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000570-78.